Does BPC-157 or TB-500 actually cause cancer? Sorting fact from fear

What did @shawnryanshow actually say?

The claim, in short: BPC-157 promotes blood vessel growth, cancer also needs blood vessels to grow, therefore BPC-157 could be feeding cancer. He also stated that TB-500 "failed" in human trials because it was "too dangerous," and that the FDA shut it down entirely. He framed the Wolverine Stack, a popular combo of BPC-157 and TB-500, as an under-discussed risk that the peptide community is ignoring.

These are not fringe ideas. The angiogenesis concern is a real conversation happening in oncology and pharmacology circles. But the way these claims were packaged, without much nuance or citation, leaves listeners with a scarier and less accurate picture than the actual science supports right now.

Does the science back this up?

Partially, but the jump from "promotes angiogenesis" to "causes cancer" is a leap the current evidence does not fully support. The angiogenesis concern is theoretically legitimate. The TB-500 claim is mostly wrong in its framing.

BPC-157 does promote angiogenesis, the formation of new blood vessels. That part is well-documented in animal models. A 2017 paper by Sikiric et al. in Current Pharmaceutical Design described BPC-157's ability to upregulate vascular endothelial growth factor (VEGF) and stimulate vessel growth in healing tissue. The concern is real: VEGF is also a known driver of tumor vascularization. Anti-VEGF drugs like bevacizumab are literally used to starve tumors by blocking this pathway.

However, promoting angiogenesis in healing tissue is not the same as causing cancer. There are zero published human studies demonstrating that BPC-157 initiates or accelerates tumor growth. The mechanistic concern is plausible, not proven.

On TB-500: the claim that the FDA "cut it completely" because it was "too dangerous" misrepresents what actually happened. Thymosin beta-4, the peptide TB-500 is based on, was studied by RegeneRx Biopharmaceuticals. Trials were halted not because of acute toxicity signals but due to lack of efficacy in later-phase trials and funding challenges. That is a different story entirely.

What did they get wrong (or right)?

Credit where it is due: the angiogenesis mechanism he describes is real, and warning a mass audience that peptides are not consequence-free is worth saying out loud. Most peptide content on TikTok reads like an ad, so raising a flag is fair.

But here is where the accuracy breaks down. First, he implies BPC-157 is actively causing cancer in users. That is not supported. A theoretical mechanism is not clinical evidence. Second, the TB-500 narrative is inaccurate. Saying the FDA found it "too dangerous to move forward" implies a toxicity finding. That is not what the trial record shows. RegeneRx's Phase III trial for corneal wound healing did not produce the efficacy results needed to continue, a different outcome entirely (RegeneRx press releases, 2017-2019).

Third, the claim that there is "not one randomized control trial done" for these peptides is an overstatement. Thymosin beta-4 derivatives have been through multiple Phase II and Phase III trials. BPC-157 human RCT data is genuinely sparse, but framing both as having zero trial history is not accurate.

What should you actually know?

The honest answer is that the risk profile of BPC-157 and TB-500 in humans is genuinely unknown, and that uncertainty cuts both ways. We do not have strong evidence they cause harm. We also do not have strong evidence they are safe at the doses people are self-administering.

The angiogenesis concern is worth taking seriously if you have a personal or family history of cancer, or if you have an active or recently treated malignancy. This is not a fringe worry. Oncologists and some sports medicine physicians have flagged VEGF-pathway peptides as a theoretical concern for cancer survivors specifically. Bitto et al. (2013, PLOS ONE) noted that pro-angiogenic interventions require more study before use in cancer-adjacent populations.

What you should not do is interpret one TikTok clip as a definitive answer. And what FormBlends will not do is recommend a peptide protocol, suggest a dose, or tell you these compounds are safe for your specific health situation. That conversation requires a licensed clinician who knows your history.

• BPC-157 is not FDA-approved for any indication in humans.
• TB-500 is not FDA-approved and is not legally available as a pharmaceutical drug in the US.
• Neither compound should be sourced from unregulated online vendors.
• If you are a cancer patient or survivor, discuss any peptide use with your oncologist before anything else.